Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Ayala Purchase Agreement Common stock	Ayala Purchase Agreement Additional Paid-in Capital	Ayala Purchase Agreement	License agreement with Zentalis Pharmaceuticals, Inc Common stock	License agreement with Zentalis Pharmaceuticals, Inc Additional Paid-in Capital	License agreement with Zentalis Pharmaceuticals, Inc	ATM Common stock	ATM Additional Paid-in Capital	ATM	Public offering Common stock	Public offering Additional Paid-in Capital	Public offering	Common stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at Dec. 31, 2022													$ 1	$ 132,653		$ (116,001)	$ 16,653
Balance (shares) at Dec. 31, 2022													12,128,843
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense														1,200			1,200
Issuance of common stock								$ 34	$ 34					221			221
Issuance of common stock ( in shares)							5,925						55,250
Vesting of restricted stock awards														24			24
Vesting of restricted stock awards (shares)													4,166
Net Income (Loss)																(4,270)	(4,270)
Balance at Mar. 31, 2023													$ 1	134,132		(120,271)	13,862
Balance (shares) at Mar. 31, 2023													12,194,184
Balance at Dec. 31, 2023													$ 4	342,663	$ 22	(222,807)	119,882
Balance (shares) at Dec. 31, 2023													43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense														2,159			2,159
Issuance of common stock		$ 50,645	$ 50,645		$ 23,388	$ 23,388				$ 2	$ 215,408	$ 215,410
Issuance of common stock ( in shares)	2,175,489			2,298,586						11,500,000
Exercise of stock options														171			$ 171
Exercise of stock options (shares)													125,704				137,112
Exercise of common stock warrants (in shares)													342,686
Unrealized loss on marketable securities															(18)		$ (18)
Net Income (Loss)																(129,492)	(129,492)
Balance at Mar. 31, 2024													$ 6	637,861	$ 4	$ (352,299)	285,572
Balance (shares) at Mar. 31, 2024													59,694,243
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock warrants														$ 3,427			$ 3,427